Global Leading Market Research Publisher QYResearch announces the release of its latest report “HER2 Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global HER2 Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For oncologists, pathologists, and molecular diagnostic laboratories, accurate determination of HER2 (human epidermal growth factor receptor 2) status is critical for treatment selection in breast and gastric cancers. Misclassification—either false-negative (missing a HER2-positive patient who could benefit from targeted therapy such as trastuzumab, pertuzumab, or T-DXd) or false-positive (exposing a HER2-negative patient to unnecessary therapy with cardiotoxicity risk)—has direct clinical and economic consequences. Traditional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods, while widely available, face challenges in inter-laboratory reproducibility, scoring standardization, and interpretation of equivocal results (IHC 2+). HER2 testing has evolved to include dual-probe FISH, chromogenic in situ hybridization (CISH), and next-generation sequencing (NGS)-based approaches, with emerging data on HER2-low expression (IHC 1+ or IHC 2+/FISH-negative) as a therapeutic target for novel antibody-drug conjugates (T-DXd, Enhertu). This report delivers a data-driven analysis of market size, market share concentration across testing platforms, cancer type segmentation (breast cancer, gastric cancer), and end-user demand drivers across hospitals, reference laboratories, and academic medical centers.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5983981/her2-testing
1. Market Size & Share Outlook: Companion Diagnostics Drive Precision Oncology Growth
The global market for HER2 testing is experiencing robust growth, driven by expanding indications for HER2-targeted therapies, the emergence of HER2-low as a treatable category, and increasing volume of HER2 testing in gastric/gastroesophageal junction cancers. While specific 2025 and 2032 valuation figures were not provided in the source material, industry consensus and published market research indicate a compound annual growth rate (CAGR) in the mid-single to low-double digits (estimated 6-9%) from 2025 through 2032, with NGS-based HER2 testing growing at 15-18% CAGR from a smaller base.
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top five manufacturers—Roche (Ventana IHC/FISH platforms), Agilent Technologies (Dako IHC/FISH), Abbott (FISH probes, molecular assays), Thermo Fisher Scientific (NGS panels, FISH probes), and Danaher (Leica Biosystems IHC platforms)—remains significant at approximately 65-70% of the global market. However, specialized and regional players (Empire Genomics/Biocare Medical, BioGenex, Abnova, Oxford Gene Technology/Sysmex) have gained market share in niche segments (custom FISH probes, research-use-only assays) and emerging markets (Asia-Pacific, Latin America), collectively holding 10-15% of the market.
Global testing volume context: Approximately 2.3 million new breast cancer cases are diagnosed annually worldwide (GLOBOCAN 2025), with 15-20% (345,000-460,000 patients) being HER2-positive by current guidelines (IHC 3+ or FISH-amplified). An additional 1.3 million gastric cancer cases are diagnosed annually, with 10-15% (130,000-195,000) HER2-positive. Beyond initial diagnosis, HER2 retesting at progression (to identify loss or gain of HER2 expression) and HER2-low testing (IHC 1+ or 2+/FISH-negative) for potential T-DXd eligibility—estimated to represent 45-55% of breast cancer patients previously classified as HER2-negative—is expanding the addressable testing market by an estimated 40-50%.
2. Technology Deep Dive: From IHC/FISH to NGS and Liquid Biopsy
HER2 testing encompasses multiple technology platforms, each with distinct sensitivity, specificity, turnaround time, and cost profiles. The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (updated 2023, 2025 addendum) specify testing algorithms and interpretation criteria.
Market segmentation by testing methodology and cancer type:
HER2 Testing for Breast Cancer (dominant segment, ~75-80% of market share) – Breast cancer HER2 testing follows a reflexive algorithm: all newly diagnosed invasive breast cancers undergo IHC (0, 1+, 2+, 3+). IHC 0/1+ = negative; IHC 3+ = positive. Equivocal (IHC 2+) cases reflex to in situ hybridization (FISH, CISH, or SISH) to assess HER2 gene amplification. FISH results reported as HER2/CEP17 ratio (≥2.0 = amplified/positive; <2.0 = non-amplified/negative). The 2025 ASCO/CAP update clarified HER2-low definition (IHC 1+ or IHC 2+/FISH-negative) as a distinct category for T-DXd eligibility, requiring pathologists to report HER2-low status systematically (previously often collapsed into “HER2-negative”).
HER2 Testing for Gastric Cancer (~20-25% of market share, growing at 8-10% CAGR) – Gastric/gastroesophageal junction HER2 testing differs from breast cancer: intratumoral heterogeneity is higher (requiring more biopsy samples), and IHC/FISH correlation is less consistent. ASCO/CAP 2025 guidelines recommend HER2 testing for all advanced gastric cancer patients, with IHC as first-line. Scoring: IHC 3+ positive, IHC 0/1+ negative, IHC 2+ reflex to FISH (HER2/CEP17 ratio ≥2.0 = positive). Emerging data suggest HER2-low gastric cancer (IHC 1+ or 2+/FISH-negative) may also benefit from T-DXd (DESTINY-Gastric02 trial), expanding testing volume.
Emerging segment: HER2 Testing via NGS and Liquid Biopsy (currently 5-8% of market share, growing at 15-20% CAGR) – Next-generation sequencing (NGS) panels (e.g., Thermo Fisher Oncomine, Roche FoundationOne, Agilent SureSelect) can detect HER2 mutations (rare, <2% of breast cancers) and copy number amplification simultaneously with other breast cancer drivers (PIK3CA, ESR1, AKT1). Liquid biopsy (circulating tumor DNA, ctDNA) for HER2 amplification detection is increasingly used for patients with insufficient tissue biopsy or to monitor resistance emergence (HER2 loss as trastuzumab resistance mechanism). However, NGS is currently more expensive (US500−1,500vs.US500−1,500vs.US 150-300 for IHC/FISH) and has longer turnaround (7-14 days vs. 1-3 days), limiting adoption to academic centers and late-line therapy selection.
Industry insight (technology platform segmentation): The HER2 testing market exhibits a classic “pyramid” structure: high-volume, low-complexity IHC (60-70% of tests, primarily in community hospitals and regional pathology labs) serves as initial screening. Moderate-volume, moderate-complexity FISH (25-30% of tests, reference labs and academic centers) resolves equivocal cases and confirms amplification. Low-volume, high-complexity NGS/liquid biopsy (<5-8% of tests, specialized molecular pathology labs) addresses therapy selection for metastatic disease, clinical trial enrollment, and resistance monitoring. This stratification creates distinct competitive dynamics: Roche and Agilent dominate the IHC and FISH installed base (estimated 70-80% of automated IHC stainers in US/EU labs), while Thermo Fisher, Illumina (partnering with Agilent/Roche), and Guardant Health (liquid biopsy) compete in the high-complexity segment. By 2030, we expect NGS/liquid biopsy to reach 12-15% of HER2 testing volume as costs decline (target US$ 300-400 per test) and turnaround improves (3-5 days).
3. Market Drivers: HER2-Low Paradigm, Expanding Indications, and Guideline Updates
Three transformative trends are accelerating the HER2 testing market:
First, the HER2-low therapeutic paradigm. The DESTINY-Breast04 trial (NEJM 2022) demonstrated that trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved progression-free survival (PFS: 10.1 vs. 5.4 months, HR 0.51) and overall survival (OS: 23.4 vs. 16.8 months, HR 0.64) in HER2-low (IHC 1+ or IHC 2+/FISH-negative) metastatic breast cancer patients who had received one or two prior lines of chemotherapy. This finding effectively redefined HER2 status from binary (positive/negative) to a continuum (HER2-0, HER2-low, HER2-positive) and increased the proportion of breast cancer patients eligible for HER2-targeted therapy from 15-20% to 60-70%. Regulatory approvals followed: FDA expanded T-DXd indication to HER2-low (August 2022), EMA (December 2022), and subsequent Asian regulatory bodies (2023-2024). ASCO/CAP 2025 guidance now mandates reporting of HER2-low status, and payers (CMS, private insurers) have established reimbursement codes specifically for HER2-low testing. The addressable HER2 testing market expanded by an estimated 2-2.5x (from ~2 million to ~5-6 million tests annually globally) for breast cancer alone, with HER2-low testing representing 3-4 million additional tests per year.
Second, expanding indications in gastric, colorectal, and other cancers. HER2 testing is now recommended for advanced gastric/gastroesophageal junction adenocarcinoma (ASCO 2024, ESMO 2025), HER2-amplified colorectal cancer (NCCN 2025 includes HER2-directed therapy for RAS/BRAF wild-type, HER2-amplified metastatic CRC), and emerging data in HER2-mutant non-small cell lung cancer (NSCLC) and biliary tract cancers. Each new indication expands the addressable market size by 200,000-500,000 additional tests annually.
Third, guideline-driven quality improvement and retesting recommendations. The 2025 ASCO/CAP HER2 testing guideline update (published Q3 2025) includes: (1) recommendation for retesting HER2 status at progression in metastatic breast cancer (10-15% of patients lose or gain HER2 expression between primary and metastatic sites); (2) expanded recommendations for HER2 testing in core needle biopsies (vs. excisional specimens) with minimum cellularity requirements (≥100 invasive tumor cells); (3) validation requirements for laboratory-developed tests (LDTs), which constitute an estimated 25-30% of HER2 testing in community settings. These guidelines drive volume and quality control investments, favoring established IVD manufacturers with FDA-cleared or CE-marked kits.
Typical user case (Q3 2025): A 58-year-old female with de novo metastatic breast cancer underwent core needle biopsy of a liver metastasis. HER2 testing by IHC at a regional hospital resulted as IHC 2+ (equivocal), reflex to FISH at a reference laboratory showed HER2/CEP17 ratio 1.6 (non-amplified, HER2-negative). The patient was initially considered HER2-negative and received chemotherapy-only. However, the oncologist requested additional HER2 testing to evaluate HER2-low status per 2025 guidelines: repeat IHC (same block, central pathology review) confirmed IHC 2+/FISH-negative = HER2-low. The patient was switched to T-DXd (trastuzumab deruxtecan) in second line. After 6 cycles: partial response (RECIST -48%), with manageable nausea (grade 2) and no interstitial lung disease (ILD). Time from initial negative HER2 result to HER2-low reclassification: 9 weeks. Total incremental testing cost: US450forrepeatIHC+centralpathologistconsultation.Estimatedcost−benefit:T−DXd(US450forrepeatIHC+centralpathologistconsultation.Estimatedcost−benefit:T−DXd(US 14,000/cycle x 6 = US84,000)vs.standardchemotherapy(US84,000)vs.standardchemotherapy(US 8,000/cycle x 6 = US$ 48,000) plus 6-month PFS advantage (14 months vs. 8 months historical control).
Policy and regulatory update (2025-2026): The FDA issued final guidance (March 2025) on “Companion Diagnostic Devices for HER2-Targeted Therapies,” clarifying premarket approval requirements for HER2 IHC and FISH assays, including analytical validation (limit of detection, specificity) and clinical validation (positive/negative percent agreement with clinical outcome). The guidance encourages dual-probe FISH over single-probe for gastric cancer testing. In Europe, the IVDR (In Vitro Diagnostic Regulation) full implementation (May 2025) reclassifies HER2 FISH kits as Class C (higher risk), requiring notified body conformity assessment—increasing compliance costs (estimated EUR 50,000-100,000 per kit) but also raising barriers for smaller competitors, potentially consolidating market share among established IVD manufacturers. China’s NMPA updated HER2 testing guidelines (July 2025) requiring all hospitals offering HER2-targeted therapies to participate in national external quality assessment (EQA) schemes, with non-compliant hospitals barred from prescribing trastuzumab/T-DXd.
4. Competitive Landscape & Regional Market Share Dynamics
The HER2 Testing market is segmented as below:
Key players:
Abbott (FISH probes, molecular assays), F. Hoffmann-La Roche Ltd (Ventana IHC platforms, FISH, NGS companion diagnostics), Agilent Technologies, Inc. (Dako IHC/FISH platforms, companion diagnostics), Thermo Fisher Scientific, Inc. (NGS panels, FISH probes, immunohistochemistry reagents), Leica Biosystems (Danaher Corporation) (IHC platforms, FISH automation), Empire Genomics, Inc. (Biocare Medical, LLC) (FISH probes, custom assays), BioGenex Laboratories (IHC/FISH platforms, automation), Abnova Corporation (IHC antibodies, FISH probes), Oxford Gene Technology IP Limited (Sysmex Corporation) (FISH probes, CISH automation)
Segment by Cancer Type:
- Breast Cancer (dominant, 75-80% of tests) – HER2-positive and HER2-low testing
- Stomach Cancer (gastric/gastroesophageal junction, 20-25% of tests, fastest-growing)
Segment by Testing Setting:
- Hospital (on-site pathology laboratories, academic medical centers) – Largest setting, particularly for IHC
- Diagnostic Reference Laboratory (centralized commercial labs) – Growing segment for FISH and NGS
- Other (academic research, clinical trial central labs)
Regional market share estimates 2025 (testing volume):
- North America: 38% (US 34%, Canada 4%) – Highest testing density and HER2-low adoption
- Europe: 28% (Germany 7%, France 5%, UK 5%, Italy 4%, others 7%) – Strong IVDR compliance, universal healthcare coverage
- Asia-Pacific: 26% (China 12%, Japan 6%, India 4%, South Korea 2%, Australia 1%) – Fastest-growing, driven by breast cancer incidence and T-DXd approvals
- Rest of World: 8% (Latin America, Middle East, Africa)
Exclusive insight (原创观察): A critical and underreported dynamic is the divergence in HER2 testing practices between Western markets (US, Western Europe) and Asia-Pacific (China, Japan, South Korea) driven by differences in HER2 prevalence, gastric cancer burden, and regulatory pathways. HER2-positive breast cancer prevalence is similar globally (15-20%), but HER2-positive gastric cancer prevalence is higher in Asia (15-20% vs. 8-12% in Western populations), leading to higher relative volume of gastric HER2 testing. China’s NMPA requires full clinical validation in Chinese patient populations (n≥500) for IVD approval, creating barriers for smaller Western manufacturers and favoring local partnerships (e.g., Roche’s Ventana platform distributed through local partners, Agilent Dako with Chinese regulatory approval). By 2028, we project China to surpass the US as the largest national HER2 testing market by volume (estimated 3-4 million tests annually vs. 2.5-3 million in US) but with lower average reimbursement (US30−50perIHCtestinChinavs.US30−50perIHCtestinChinavs.US 100-150 in US commercial insurance). This volume-driven but price-sensitive market will favor manufacturers with low-cost automation and high-throughput platforms.
5. Technical Hurdles and Future Research Directions
Despite standardization efforts, significant technical and interpretive challenges remain:
- Inter-laboratory reproducibility and scoring variability: Published studies report concordance rates of 85-90% for IHC 3+ and IHC 0, but only 60-70% for IHC 1+ (HER2-low) and IHC 2+ (equivocal). Automated image analysis and AI-assisted scoring (e.g., Leica’s Aperio, Roche’s DP200, Agilent’s PharmDx AI under development) show promise but require regulatory clearance and reimbursement.
- HER2 heterogeneity in gastric cancer: Gastric cancer often shows focal or mosaic HER2 expression (positivity in <30% of tumor cells in some cases), increasing risk of false-negative biopsies. ASCO/CAP 2025 recommends testing at least 5-8 biopsy samples (vs. 1-2 for breast), increasing testing cost (US$ 500-1,000 per case) and pathologist time.
- HER2 status discordance between primary and metastatic sites: Up to 15-20% of breast cancer patients show HER2 status change (loss or gain) at recurrence. Retesting requires obtaining metastatic biopsy (invasive procedure, often not performed in advanced disease). Liquid biopsy (ctDNA) for HER2 amplification offers non-invasive alternative but has lower sensitivity (70-75%) for low-copy number amplifications.
Future Market Research priorities should address:
- Artificial intelligence for HER2 scoring and HER2-low identification – Automated classification of IHC 1+ (HER2-low) vs. IHC 0, which remains challenging (low signal-to-noise ratio), requires deep learning models trained on large annotated datasets
- Multiplex IHC for simultaneous HER2, ER, PR, and Ki67 – Reducing tissue consumption (critical for small biopsies) and turnaround time; emerging platforms (Roche DISCOVERY, Leica BOND) support 4-6-plex staining
- Standardized reference materials and calibrators – Traceable HER2 reference standards (IHC intensity controls, FISH ratio calibrators) to harmonize results across laboratories; WHO International Standard (coded 19/280) for HER2 IHC exists but limited adoption
- HER2 testing for emerging therapy selection – Antibody-drug conjugates targeting HER2 (T-DXd, T-DM1) may benefit from quantitative HER2 expression levels (not just binary positive/low/negative), driving demand for quantitative immunofluorescence (QIF) or digital pathology-based continuous scoring
- Point-of-care HER2 testing – Rapid (30-60 minute) HER2 IHC or molecular assays for community settings without on-site pathology; emerging technologies including lateral flow immunoassays and CRISPR-based amplification detection
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
